Helicobacter pylori infection--current treatment practice

Expert Opinion on Pharmacotherapy
H H XiaS K Lam

Abstract

Helicobacter pylori infection, which is present in 30 - 60% of the population in developed countries and in more than 60% in developing countries, is established to be a major cause of gastritis, peptic ulcer disease and gastric cancer. Eradication therapy has been incorporated into clinical practice over the past 15 years. Treatment regimens include a 2 week bismuth-based triple therapy (a bismuth compound plus metronidazole, tetracycline or amoxycillin), a 1 week proton-pump inhibitor (PPI)-based triple therapy and a 1 week ranitidine bismuth citrate (RBC)-based triple therapy (a PPI or RBC plus any two of the three antibiotics, metronidazole, amoxycillin and clarithromycin). These regimens achieve eradication rates of > 80%. H. pylori resistance to metronidazole and clarithromycin decreases the clinical efficacy of most regimens, despite the high eradication rates for resistant strains achieved by the RBC-triple therapy in some recent trials. The dose of antibiotics (especially clarithromycin) and the duration of treatment may also influence the eradication rate. Doctors' beliefs impact on clinical practice and, thus, influence the clinical application of eradication therapy. Whereas peptic ulcer disease and primary gastric ...Continue Reading

References

Jan 1, 1992·Antimicrobial Agents and Chemotherapy·H RautelinT U Kosunen
Nov 16, 1991·Lancet·R P LoganJ H Baron
Jul 1, 1991·The American Journal of Medicine·Y M NenseyC K Ma
May 8, 1995·Archives of Internal Medicine·A Sonnenberg, W F Townsend
Feb 1, 1995·Alimentary Pharmacology & Therapeutics·G D BellC Brown
Jul 1, 1996·Journal of Gastroenterology and Hepatology·G M ForbesB J Collins
Feb 1, 1997·Alimentary Pharmacology & Therapeutics·G Vautier, B B Scott
Apr 1, 1997·Archives of Disease in Childhood·D WalshB Drumm
Jun 1, 1997·Scandinavian Journal of Gastroenterology·J GilvarryC A O'Morain
Aug 1, 1997·Alimentary Pharmacology & Therapeutics·V SavarinoG Celle
Mar 28, 1998·The American Journal of Gastroenterology·H H Xia, N J Talley
Jul 4, 1998·Pediatrics·J F LeckmanB S Peterson
Jul 25, 1998·Alimentary Pharmacology & Therapeutics·N J TalleyC Tseng-Shing

❮ Previous
Next ❯

Citations

Jun 1, 2002·Microbiology and Molecular Biology Reviews : MMBR·Ronald Bentley, Thomas G Chasteen
Aug 21, 2002·Expert Opinion on Pharmacotherapy·Harry Hua-Xiang XiaShiu Kum Lam

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Atrophic Gastritis

Atrophic Gastritis is a process where gastric glandular cells are lost and replaced with firbous tissues, as a result of chronic inflammation. Learn more about Atrophic Gastritis here.